Apimeds Pharmaceuticals and MindWave Innovations Merge to Integrate Biotech and AI-Driven Digital Treasury Solutions

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) and MindWave Innovations Inc. have officially announced their merger, bringing together a clinical-stage biotech company and a leading provider of institutional Bitcoin treasury solutions. This strategic union is designed to establish a versatile growth-focused entity, with Apimeds specializing in innovative non-opioid pain treatments while MindWave brings its advanced AI-powered Bitcoin yield platform and the ecosystem supported by the $NILA token.

The merger was facilitated by E.F. Hutton, who acted as the exclusive M&A advisor and placement agent for a concurrent Private Investment in Public Equity (PIPE) financing round, which could potentially raise up to $100 million in funding for the newly formed entity.